Guideline on the Management of Dyslipidemia
The new 2026 ACC/AHA/AACVPR et al. Guidelines for the Management of Dyslipidemia have been published. These guidelines address the assessment, treatment, and monitoring of individuals with dyslipidemia, including high blood cholesterol, elevated triglycerides, and elevated lipoprotein(a) [Lp(a)]. These new guidelines address primary, secondary, and primary prevention, provide guidance for care of adults and children, reinstate risk-based treatment targets for low-density lipoprotein (LDL) cholesterol, and replace the 2018 AHA/ACC/Multisociety Cholesterol Treatment Guidelines.
Quadpill Strategy Gains Ground in Hypertension
Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension. Agents such as baxdrostat, the first selective aldosterone synthase inhibitor, and aprocitentan, a dual endothelin receptor A and B antagonist, are paving the way for new drug combinations and a more personalized approach to blood pressure control.
ADA Advises Against Using Compounded GLP-1 RA Medications
In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.
New Pill Successfully Lowers Lp(a) Levels
Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show.
The results of the 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology 2024
The anniversary 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology were held in Beijing at the National Exhibition Center on November 7-10, 2024.
As part of the four-day congress, 415 scientific sessions were organized and 2177 reports were made on various areas of cardiology. The congress was attended by 23,980 national and international experts, professors and specialists from almost 40 countries from all the continents of the world.
New State Law Will Restrict AI in Prior Authorization, Coverage Decisions
California is taking aim at algorithms used by insurers to make prior authorization and other coverage decisions with a new law that will put limitations on how artificial intelligence (AI)–generated formulas are employed.
Development and validation of a machine learning model to predict myocardial blood flow and clinical outcomes from patients’ electrocardiograms
Scientists have developed a machine learning (ML) model using electrocardiography (ECG) to predict myocardial blood flow reserve (MFR) and assess its predictive value in relation to major adverse cardiovascular events (MACEs). Using 3639 ECG positron emission tomography (PET) and 17,649 pairs of ECG single-photon emission computed tomography data (SPECT), the model is trained using the intelligent swarm intelligence approach and support vector regression (SVR).
New Scanner Creates Highly Detailed, 3D Images of Blood Vessels in Just Seconds
A new scanner can provide three-dimensional (3D) photoacoustic images of millimeter-scale veins and arteries in seconds.
Nobel Prize in medicine goes to two American biologists for work on the discovery of microRNA
The 2024 Nobel Prize in physiology or medicine has been awarded to US scientists Victor Ambros and Gary Ruvkun for their work on the discovery of microRNA, a molecule that governs how cells in the body function.
RU
EN